Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:28:04.755Z.
Calculation as of: 2026-10-06T17:28:04.755Z.
Quote observation: 2026-10-06T17:25:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 772026cfaa68636964238f2a0be34d7b7ee81ab44c33f4f711fca00153048be4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Ultragenyx Pharmaceutical Inc.
Market Cap
$1.42B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.43B
EBITDA Yield
N/A
TTM Avg
19.73%
3Y Avg
19.73%
5Y Avg
19.73%
Market Cap
$1.41B
EBITDA Yield
3.90%
TTM Avg
3.95%
3Y Avg
3.70%
5Y Avg
2.96%
Market Cap
$1.45B
EBITDA Yield
11.19%
TTM Avg
6.15%
3Y Avg
7.10%
5Y Avg
6.61%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | $1.42B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.43B | N/A | 19.73% | 19.73% | 19.73% |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 3.90% | 3.95% | 3.70% | 2.96% |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 8.78% | 3.11% | 3.11% | 3.25% |
| Certara, Inc. (CERT)vs › | $1.44B | 3.81% | 6.63% | 3.69% | 3.19% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 11.19% | 6.15% | 7.10% | 6.61% |
| GH Research PLC (GHRS)vs › | $1.46B | N/A | N/A | N/A | N/A |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.46B | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
